Citracal ad claims
This article was originally published in The Tan Sheet
Executive Summary
National Advertising Division of the Council of Better Business Bureaus concludes unqualified marketing claims that Mission Pharmacal's Citracal is "better absorbed than calcium carbonate" should be discontinued. Group also found superior solubility claims made in the absence of superior absorption statements would be supported by the firm's in vitro data if "carefully qualified." Concluded May 5, inquiry was prompted by GlaxoSmithKline, marketer of OsCal supplements with calcium carbonate. NAD's recommendations reflect and confirm January decision by National Advertising Review Board regarding similar Citracal claims and supporting data. That case involved a challenge by Caltrate marketer Wyeth Consumer Healthcare (1"The Tan Sheet" Aug. 5, 2002, p. 7)...
You may also be interested in...
Citracal Quantified Calcium Absorption Superiority Claims Unproven – NAD
Quantified claims that Mission Pharmacal's Citracal calcium supplement is better absorbed than calcium carbonate are not supported by the submitted clinical trials and should be discontinued, NAD concludes in an upcoming NAD Case Reports
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.